Scientific considerations in the review and approval of generic enoxaparin in the United States
暂无分享,去创建一个
Andre Raw | Lawrence X. Yu | Lawrence Yu | Janet Woodcock | Daniela Verthelyi | Robert Lionberger | Sau Lee | Naiqi Ya | Amy Rosenberg | Steve Kozlowski | Keith Webber | J. Woodcock | R. Lionberger | A. Raw | S. Lee | A. Rosenberg | D. Verthelyi | S. Kozlowski | Keith R. Webber | N. Ya
[1] D. Bergqvist,et al. Recommendations on biosimilar low‐molecular‐weight heparins , 2009, Journal of thrombosis and haemostasis : JTH.
[2] E. Kalodiki,et al. SASAT (South Asian Society on Atherosclerosis & Thrombosis) Proposal for Regulatory Guidelines for Generic Low-molecular Weight Heparins (LMWHs) , 2009, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
[3] A. García‐Arieta,et al. Regulatory considerations for generic or biosimilar low molecular weight heparins. , 2012, Current drug discovery technologies.
[4] G. Merli,et al. Applying Scientific Criteria to Therapeutic Interchange: A Balanced Analysis of Low-Molecular-Weight Heparins , 2001, Journal of Thrombosis and Thrombolysis.
[5] S. Olson,et al. Heparin Enhances the Specificity of Antithrombin for Thrombin and Factor Xa Independent of the Reactive Center Loop Sequence , 2001, The Journal of Biological Chemistry.
[6] Steven Kozlowski,et al. Developing the nation's biosimilars program. , 2011, The New England journal of medicine.
[7] L. Rabenstein,et al. Chromatographic methods for product-profile analysis and isolation of oligosaccharides produced by heparinase-catalyzed depolymerization of heparin. , 2001, Journal of chromatography. A.
[8] A. Greinacher,et al. Heparin‐induced thrombocytopenia: a prospective study on the incidence, platelet‐activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes , 2007, Journal of thrombosis and haemostasis : JTH.
[9] B. White,et al. Concentration-dependent roles for heparin in modifying liopolysaccharide-induced activation of mononuclear cells in whole blood , 2008, Thrombosis and Haemostasis.
[10] G. Montalescot,et al. US Food and Drug Administration approval of generic versions of complex biologics: implications for the practicing physician using low molecular weight heparins , 2012, Journal of Thrombosis and Thrombolysis.
[11] Robert J Linhardt,et al. Liquid Chromatography/Mass Spectrometry Sequencing Approach for Highly Sulfated Heparin-derived Oligosaccharides* , 2004, Journal of Biological Chemistry.
[12] G. Torri,et al. Quantitative 2D NMR Analysis of Glycosaminoglycans , 2008 .
[13] F. Schmidt. Meta-Analysis , 2008 .
[14] R. Sasisekharan,et al. Heparin and heparan sulfate: biosynthesis, structure and function. , 2000, Current opinion in chemical biology.
[15] W. Chuang,et al. Determination of the primary structures of heparin- and heparan sulfate-derived oligosaccharides using band-selective homonuclear-decoupled two-dimensional 1H NMR experiments. , 2001, Analytical chemistry.
[16] M. Samama,et al. Comparative Pharmacokinetics of LMWHs , 2000, Seminars in thrombosis and hemostasis.
[17] Zengji Li,et al. Analysis of non-covalent aggregation of synthetic hPTH (1-34) by size-exclusion chromatography and the importance of suppression of non-specific interactions for a precise quantitation. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[18] L. Rauova,et al. Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. , 2005, Blood.
[19] E. Ohman,et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. , 2001, Chest.
[20] J. Turnbull,et al. A strategy for rapid sequencing of heparan sulfate and heparin saccharides. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[21] J. Harenberg. Differences of Present Recommendations and Guidelines for Generic Low-Molecular-Weight Heparins: Is There Room for Harmonization , 2011, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
[22] S. Levin. Field flow fractionation in biomedical analysis. , 1991, Biomedical chromatography : BMC.
[23] Robert C. Wolpert,et al. A Review of the , 1985 .
[24] G. Torri,et al. Combined Quantitative 1H and 13C Nuclear Magnetic Resonance Spectroscopy for Characterization of Heparin Preparations , 2001, Seminars in thrombosis and hemostasis.
[25] D. Hoppensteadt,et al. Product Individuality of Commercially Available Low-Molecular-Weight Heparins and Their Generic Versions: Therapeutic Implications , 2006, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
[26] F. Ofosu. A review of the two major regulatory pathways for non-proprietary low-molecular-weight heparins , 2012, Thrombosis and Haemostasis.
[27] Y. Lokhnygina,et al. Platelet factor 4/heparin antibodies in blood bank donors. , 2010, American journal of clinical pathology.
[28] U. Lindahl,et al. Mode of interaction between platelet factor 4 and heparin. , 1993, Glycobiology.
[29] K. Yoshida,et al. Structural studies of octasaccharides derived from the low-sulfated repeating disaccharide region and octasaccharide serines derived from the protein linkage region of porcine intestinal heparin. , 1999, Biochemistry.
[30] R. Linhardt. 2003 Claude S. Hudson Award address in carbohydrate chemistry. Heparin: structure and activity. , 2003, Journal of medicinal chemistry.
[31] M. Heinzelmann,et al. Heparin and enoxaparin enhance endotoxin-induced tumor necrosis factor-alpha production in human monocytes. , 1999, Annals of surgery.
[32] R. Langer,et al. Enzymatic degradation of glycosaminoglycans. , 1995, Critical reviews in biochemistry and molecular biology.
[33] C. Boudier,et al. Effects on molecular conformation and anticoagulant activities of 1,6-anhydrosugars at the reducing terminal of antithrombin-binding octasaccharides isolated from low-molecular-weight heparin enoxaparin. , 2010, Journal of medicinal chemistry.
[34] T. Kiziltepe,et al. Molecular cloning of the heparin/heparan sulfate delta 4,5 unsaturated glycuronidase from Flavobacterium heparinum, its recombinant expression in Escherichia coli, and biochemical determination of its unique substrate specificity. , 2002, Biochemistry.
[35] G. Agnelli,et al. Management of Oral Anticoagulant Therapy in Italy , 1999, Seminars in thrombosis and hemostasis.
[36] Z. Shriver,et al. Sequencing complex polysaccharides. , 1999, Science.
[37] P. Mourier,et al. Chromatographic analysis and sequencing approach of heparin oligosaccharides using cetyltrimethylammonium dynamically coated stationary phases. , 2004, Analytical biochemistry.
[38] R. Sasisekharan,et al. Structural features of low-molecular-weight heparins affecting their affinity to antithrombin , 2009, Thrombosis and Haemostasis.
[39] B. Chong,et al. Heparin-induced Thrombocytopenia: IgG Binding to PF4-Heparin Complexes in the Fluid Phase and Cross-reactivity with Low Molecular Weight Heparin and Heparinoid , 1998, Thrombosis and Haemostasis.
[40] R. Linhardt,et al. Production and chemical processing of low molecular weight heparins. , 1999, Seminars in thrombosis and hemostasis.
[41] R. Linhardt,et al. Heparin-protein interactions. , 2002, Angewandte Chemie.
[42] S. Nightingale. Appropriate Use of Low-Molecular-Weight Heparins (LMWHs) , 1993 .
[43] J. Harenberg. Overview on guidelines and recommendations for generic low-molecular-weight heparins. , 2011, Thrombosis research.
[44] A. Greinacher,et al. Characterization of the Structural Requirements for a Carbohydrate Based Anticoagulant with a Reduced Risk of Inducing the Immunological Type of Heparin-associated Thrombocytopenia , 1995, Thrombosis and Haemostasis.
[45] A. Greinacher,et al. Incidence and clinical relevance of anti-platelet factor 4/heparin antibodies before cardiac surgery. , 2010, American heart journal.
[46] Marc S. Lewis,et al. Modern analytical ultracentrifugation in protein science: A tutorial review , 2002, Protein science : a publication of the Protein Society.
[47] 로저 데브리. Mixtures of particular lmw heparinic polysaccharides for the prophylaxis/treatment of acute thrombotic events , 1991 .
[48] R. Langer,et al. Rational design of low-molecular weight heparins with improved in vivo activity , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[49] K. Biemann,et al. Sequencing of 3-O sulfate containing heparin decasaccharides with a partial antithrombin III binding site. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[50] P. Wells,et al. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. , 2005, Blood.
[51] M. Poncz,et al. Determinants of PF4/heparin immunogenicity. , 2007, Blood.
[52] F. Fabris,et al. Heparin-induced thrombocytopenia. , 2000, Haematologica.
[53] R. Rosenberg. Actions and interactions of antithrombin and heparin. , 1975, The New England journal of medicine.
[54] M. Nugent. Heparin sequencing brings structure to the function of complex oligosaccharides. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[55] A. Girolami,et al. Heparin-induced thrombocytopenia: a review. , 2006, Seminars in thrombosis and hemostasis.
[56] B. Eriksson,et al. A Comparative Study of Three Low-molecular Weight Heparins (LMWH) and Unfractionated Heparin (UH) in Healthy Volunteers , 1995, Thrombosis and Haemostasis.
[57] R. Linhardt,et al. Mapping and quantification of the major oligosaccharide components of heparin. , 1988, The Biochemical journal.
[58] J. Fareed,et al. In vitro studies on the biochemistry and pharmacology of low molecular weight heparins. , 1999, Seminars in thrombosis and hemostasis.
[59] U. Holzgrabe,et al. NMR spectroscopy in pharmaceutical analysis , 2008 .
[60] W. Weitschies,et al. Close Approximation of Two Platelet Factor 4 Tetramers by Charge Neutralization Forms the Antigens Recognized by HIT Antibodies , 2006, Arteriosclerosis, thrombosis, and vascular biology.
[61] U Lindahl,et al. Minimal sequence in heparin/heparan sulfate required for binding of basic fibroblast growth factor. , 1994, The Journal of biological chemistry.
[62] J. Hirsh,et al. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.
[63] H. Büller,et al. Prevention of Deep Vein Thrombosis after Hip Replacement , 1999, Thrombosis and Haemostasis.
[64] H. Toyoda,et al. Rapid and sensitive analysis of disaccharide composition in heparin and heparan sulfate by reversed-phase ion-pair chromatography on a 2 μm porous silica gel column , 1999 .